ArticleClinical pharmacology and therapeutics2014
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.
Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.Saudi medical journal · 2016Pooled it
- Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists.Journal of internal medicine · 2023Article
- Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland.Clinical epidemiology · 2021Article
- Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery.Indian journal of thoracic and cardiovascular surgery · 2019Article
- Pharmacogenomics.Lancet (London, England) · 2019Review
- Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.Clinical pharmacology and therapeutics · 2018Review
- Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.Circulation research · 2018Review
- The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska.Molecular nutrition & food research · 2018Article
- Pharmacogenetic Implementation Lessons From the "Real World".Clinical pharmacology and therapeutics · 2017Article
- Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.The American journal of medicine · 2017Article
- VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Medicine · 2016Article
- Genetic determinants of variability in warfarin response after the dose-titration phase.Pharmacogenetics and genomics · 2016Article
- Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.Pharmacotherapy · 2016Article
- Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2016Article
- Integrating electronic health record genotype and phenotype datasets to transform patient care.Clinical pharmacology and therapeutics · 2016Article
- Cardiovascular pharmacogenomics: current status and future directions.Journal of human genetics · 2016Review
- Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.Pharmacogenetics and genomics · 2015Article
- Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.Pharmacoepidemiology and drug safety · 2015Article
- Conflicting forces of warfarin and matrix gla protein in the artery wall.Arteriosclerosis, thrombosis, and vascular biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The influence of warfarin pharmacogenomics on major bleeding risk has been little studied in long-term users and non-specialist care settings. We conducted a case-control study to evaluate associations between CYP2C9*2/*3, VKORC1(1173), and CYP4F2*3 variants and major bleeding among patients treated with warfarin in a community setting. We calculated major bleeding odds ratios, adjusting for race, duration of warfarin use, age, gender, and body mass index. In 265 cases and 305 controls with 3.4 and 3.7 mean years of warfarin use, respectively, CYP4F2*3 was associated with decreased major bleeding risk (odds ratio: 0.62; 95% confidence interval: 0.43-0.91). CYP2C9*2/*3 and VKORC1(1173) had null associations overall, but there was a nonsignificant increase in major bleeding risk in patients with duration <6 months (odds ratio: 1.30; 95% confidence interval: 0.60-2.83; odds ratio: 1.23; 95% confidence interval: 0.57-2.64, respectively). In summary, in the largest study of warfarin pharmacogenomics and major bleeding to date, we found a 38% lower risk in patients with CYP4F2*3, potentially reflecting interaction with warfarin and dietary vitamin K intake and warranting additional evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.